Peptides for fat loss, ranked by evidence
This is the goal with the widest gap between what is proven and what is sold. Two of the compounds below have changed outcomes in trials of tens of thousands of people. Most of the rest have never been tested in a human being for weight loss at all, and several were tested and failed.
- Compounds people use for this
- 19
- Approved for any indication
- 6
- Preliminary evidence or none
- 6
- Best-evidenced
- Liraglutide and Semaglutide
A rank is a statement about evidence, not advice. Position here is calculated from the published evidence rating, regulatory standing and documented risks on each monograph. It says nothing about whether a compound is appropriate for you, and several of the best-evidenced entries are prescription medicines that carry serious warnings. Nothing on this page is a recommendation, and no page on this site states a dose.
The best-evidenced options here are prescription medicines, and they carry their own warnings. Being top of this table means the evidence is strong, not that the drug is right for you.
Ranked by the same evidence score used across the site, restricted to the compounds people actually take for this. A compound near the bottom is not necessarily useless — it is untested, which is a different and more common situation. Every row links to a monograph that says exactly what was studied and in whom.
| # | Compound | Status | Evidenceout of 100 | Riskout of 100 | Gaprisk − evidence | Why it sits here |
|---|---|---|---|---|---|---|
| 1 | Liraglutide Metabolic & Weight · Victoza | FDA Approved | 98 | 39 | -59 | FDA Approved. 4 benefit claims on strong human evidence. 2 serious or common risks. |
| 1 | Semaglutide Metabolic & Weight · Ozempic | FDA Approved | 98 | 63 | -35 | FDA Approved. 4 benefit claims on strong human evidence. 3 serious or common risks. |
| 3 | Exenatide Metabolic & Weight · Byetta | FDA Approved | 95 | 47 | -48 | FDA Approved. 4 benefit claims on strong human evidence. 2 serious or common risks. |
| 4 | Setmelanotide Metabolic & Weight · Imcivree | FDA Approved | 93 | 30 | -63 | FDA Approved. 3 benefit claims on strong human evidence. 1 serious or common risk. |
| 4 | Tirzepatide Metabolic & Weight · Mounjaro | FDA Approved | 93 | 63 | -30 | FDA Approved. 3 benefit claims on strong human evidence. 3 serious or common risks. |
| 6 | Dulaglutide Metabolic & Weight · Trulicity | FDA Approved | 91 | 40 | -51 | FDA Approved. 2 benefit claims on strong human evidence. 2 serious or common risks. |
| 7 | Mazdutide Metabolic & Weight · IBI362 | Limited Approval | 71 | 42 | -29 | Limited Approval. 2 benefit claims on strong human evidence. 1 serious or common risk. |
| 8 | Orforglipron Metabolic & Weight · LY3502970 | In Clinical Trials | 70 | 49 | -21 | In Clinical Trials. 3 benefit claims on strong human evidence. 2 serious or common risks. |
| 9 | GHRP-2 Growth Hormone Axis · Pralmorelin | Limited Approval | 54 | 47 | -7 | Limited Approval. 1 benefit claim on strong human evidence. 2 serious or common risks. |
| 10 | Cagrilintide Metabolic & Weight · CagriSema (with semaglutide) | In Clinical Trials | 49 | 46 | -3 | In Clinical Trials. No benefit claim on strong human evidence. 2 serious or common risks. |
| 10 | MK-677 (Ibutamoren) Growth Hormone Axis · Ibutamoren | Not a Peptide | 49 | 77 | +28 | Not a Peptide. 2 benefit claims on strong human evidence. 4 serious or common risks. |
| 10 | Retatrutide Metabolic & Weight · LY3437943 | In Clinical Trials | 49 | 64 | +15 | In Clinical Trials. No benefit claim on strong human evidence. 3 serious or common risks. |
| 10 | Survodutide Metabolic & Weight · BI 456906 | In Clinical Trials | 49 | 55 | +6 | In Clinical Trials. No benefit claim on strong human evidence. 2 serious or common risks. |
| 14 | AOD-9604 Metabolic & Weight · hGH fragment 176-191 | Research Use Only | 30 | 59 | +29 | Research Use Only. No benefit claim on strong human evidence. 2 serious or common risks. |
| 14 | CJC-1295 Growth Hormone Axis · Modified GRF (1-29) | Research Use Only | 30 | 91 | +61 | Research Use Only. No benefit claim on strong human evidence. 5 serious or common risks. |
| 14 | GHRP-6 Growth Hormone Axis · Growth Hormone Releasing Hexapeptide | Research Use Only | 30 | 69 | +39 | Research Use Only. No benefit claim on strong human evidence. 2 serious or common risks. |
| 14 | Ipamorelin Growth Hormone Axis · NNC 26-0161 | Research Use Only | 30 | 91 | +61 | Research Use Only. No benefit claim on strong human evidence. 3 serious or common risks. |
| 18 | 5-Amino-1MQ Metabolic & Weight · 5-amino-1-methylquinolinium | Not a Peptide | 15 | 89 | +74 | Not a Peptide. No benefit claim on strong human evidence. 4 serious or common risks. |
| 18 | Adipotide Bone, Muscle & Other · FTPP | Research Use Only | 15 | 82 | +67 | Research Use Only. No benefit claim on strong human evidence. 4 serious or common risks. |
How this ranking is built
| Evidence rating | 15 points each, up to 75 The published 1-5 rating, multiplied by fifteen. This is most of the score, because it is the thing the whole site is built to assess. |
|---|---|
| Regulatory standing | FDA Approved 12 · Limited Approval 7 · In Clinical Trials 4 · Cosmetic Ingredient 2 Approval by a major regulator means an agency has reviewed the trial data and agreed. Approval elsewhere, or an active registered trial, counts for less. A research-use-only label counts for nothing. |
| Well-supported benefit claims | 2 points each, up to 10 Two points for each benefit on the monograph carried by strong human evidence, up to five of them. A long list of weakly-supported claims adds nothing here. |
| Hard clinical endpoints | up to 3 Three points where a well-supported claim rests on something that happened to a patient — a death, a fracture, a heart attack, a transplant, a remission — rather than on a number that moved in a blood test. This is the site's published tie-breaker between two drugs that both have strong trials. |
Membership is computed from each monograph's category, tags and benefit claims rather than chosen by hand, so a compound added to the library appears here on its own. The score is the site-wide evidence score, not a score for this goal specifically — a compound approved for something else does not get credit here for that approval beyond its regulatory standing. Read the evidence scale for what the tiers mean.
The other things people ask about
See also the whole library ranked by evidence and by documented risk.